AVL 3288

Drug Profile

AVL 3288

Alternative Names: Anvylic-3288; AVL-3288; UCI-4083

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anvyl Pharmaceuticals
  • Developer Anvyl
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cognition disorders

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 16 Sep 2017 University of Maryland plans a phase I trial for Cognition disorders (NCT03281694)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2016 New York State Psychiatric Institute and National Institute of Mental Health initiate a phase I trial for Cognition disorders associated with schizophrenia in USA (PO) (NCT02978599)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top